Drugs / TCN-032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01390025 | Sep 2011 → Mar 2012 | influenza | Theraclone Sciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01719874 | Aug → Dec 2012 | influenza | Theraclone Sciences, Inc. | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCN-032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01719874 ↗ |
| Modality | Monoclonal antibody | “TCN-032 is a human monoclonal antibody” NCT01390025 ↗ |
| Route | Intravenous | “a single intravenous administration of TCN-032” NCT01390025 ↗ |